An interventional study of Total hip replacement and Blood sampling in Sarcopenia in Elderly, Osteoarthritis (OA) and Hip Fracture Surgeries, sponsored by University Hospital, Montpellier. Recruiting at 1 site in France. Open to participants aged 75 Years and older. Per ClinicalTrials.gov, last updated 2026-09-10.
Sponsored by University Hospital, Montpellier · Not applicable, Interventional, and Screening
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 136 studies in Osteoarthritis with a site in France — 25 open to participants now, 38 under way, 2 of them phase 3. Osteoarthritis · France.
Among the 136 studies in Osteoarthritis with a site in France, this one is the 74th largest by planned enrollment of the 86 interventional ones that give a count, is one of 9 that started in 2026, is one of 48 with no phase, reaches primary completion later than 20 of the 37 other live ones, and was the 128th registered.
2,978 studies on the registry are indexed under Osteoarthritis; 438 are open to participants now.
Browse Osteoarthritis studies →25 of the 136 studies in Osteoarthritis with a site in France are open now. Recruiting first, the newest first:
TBF Genie Tissulaire · Sites in France
Ages 18–75
Centre Hospitalier Universitaire de Nice · Sites in France
Ages 40–85
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Nantes University Hospital · Sites in France
Ages 18+
Groupe Hospitalier Diaconesses Croix Saint-Simon · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 285 Osteoarthritis studies recruiting now, 158 (55%) set no upper age limit and 70 (25%) stop at 75 or younger; 22 take children under 18; 31 take healthy volunteers.
This study: 75 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
136 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 19 · Phase 3 15 · Phase 4 6
First in 1999; this study’s year is marked. 9 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 80 across 2,242 interventional studies indexed under Osteoarthritis.
Median enrollment 90 across the 86 interventional studies, 152 across the 48 observational. Of the 83 that completed or were terminated, 12 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
49 of 136 have an industry lead sponsor. The 10 most frequent:
University Hospital, Montpellier is the lead sponsor of 1,264 studies on the registry; 226 are open to participants now.
University Hospital, Montpellier has 9 studies filed under Osteoarthritis — fewer than ten, so there is no comparison to draw.
10 of the studies in Osteoarthritis with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06902805Phase 3Assistance Publique - Hôpitaux de ParisEfficacy of Two Ultrasound-guided Intra-articular Injections of Botox® Combined With Custom-made Rigid Splinting in Painful Base-of-thumb Osteoarthritis. | 2027-05 |
| NCT06038331TBF Genie TissulaireUse of a Treated, Devitalized and Sterile Umbilical Cord Amniotic Membrane in the Treatment of STT Osteoarthritis | 2026-11 |
| NCT07812701Assistance Publique - Hôpitaux de ParisTopical Clobetasol Propionate for Inflammatory Hand Osteoarthritis | 2026-11 |
| NCT02337244Zimmer, GmbHZimmer POLAR Persona - TKA (EMEA Study) | 2026-12 |
| NCT03372278Zimmer BiometPMCF Study on the Safety and Performance of the Zimmer® Maxera™ Acetabular System in Total Hip Arthroplasty | 2027-01 |
Add all 10 to your calendar (.ics) → With an account.
Among the 136 studies in Osteoarthritis with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This single-centre, exploratory study at Montpellier University Hospital will investigate whether having low muscle mass and strength before hip-replacement surgery, a condition called sarcopenia, impact the return to everyday independence in people aged 75 years or older. About 20 volunteers, scheduled for surgery because of a recent femoral-neck fracture or severe arthritis that no longer responds to usual care, will give consent, answer brief health questionnaires, attempt simple walking and chair-rise tests if possible, and provide a small blood sample. While they are already under anaesthesia for their planned operation, the surgical team will take a tiny muscle sample through the same incision, so no extra cuts are needed. During the hospital stay or shortly after discharge, each participant will have a painless MRI scan of the thigh muscles and a very-low-dose bone scan (DXA) to measure muscle and bone health. The research team will then telephone participants at 3 and 6 months to ask about daily activities, walking ability, and any complications. The study lasts about six months for each person and does not alter their usual medical or rehabilitation care. Potential benefits include close follow-up, personalised feedback on muscle and bone results, and helping doctors learn whether pre-surgery muscle weakness predicts slower recovery-information that could guide future, more personalised exercise and nutrition programs. Extra study procedures carry only minimal risks: a routine blood draw, scans with none (MRI) or very little (DXA) radiation, and a muscle biopsy taken during surgery. Taking part is entirely voluntary, and participants may withdraw at any time without affecting their current or future care. The whole project will run for 18 months.
Hip-REGEN is an exploratory, single-centre, prospective, longitudinal pathophysiology study conducted at Montpellier University Hospital to clarify whether the degree of pre-operative sarcopenia modulates functional recovery after hip arthroplasty in patients ≥ 75 years who undergo the procedure either for a recent femoral-neck fracture or severe hip osteoarthritis.
The increasing worldwide burden of musculoskeletal diseases, represents major costs for the healthcare system. Osteoarthritis, which affects around 595 million people worldwide, and osteoporosis, defined by the WHO as a reduction in bone mineral density, are two of the main age-related musculoskeletal pathologies. In France, between 2008 and 2014, around 650,000 hip prostheses surgeries were necessary to treat severe coxofemoral osteoarthritis, and around 65,000 hip prostheses surgeries are necessary every year to treat fractures of the upper end of the femur, occuring mainly due to osteoporosis, associated with significant loss of autonomy and high one-year mortality rate (20%).
We hypothesise that lower muscle mass and strength before surgery will negatively impact the 3- and 6-month functional recovery, assessed by the Barthel Index. This association could be mediated by impaired muscle regenerative capacity and endocrine function, including myokines and related systemic circulating biomarkers. Twenty participants (10 hip fractures, 10 hip osteoarthritis) will be consecutively enrolled over 12 months, in the orthopaedic service, a sample size chosen to demonstrate feasibility and to cover the cost of ex-vivo assays while maintaining balanced sex representation. After written informed consent, baseline (Visit 1) assessments include Barthel Index, Katz ADL, Lawton IADL, physical activity (IPAQ-SF), SARC-F, comorbidity (Charlson), nutritional and cognitive screens, hand-grip dynamometry, and blood sampling for biobanking. Pre-operative sarcopenia status is classified according to EWGSOP2 thresholds for grip strength and appendicular lean mass by DXA (Visit 3), complemented by quantitative MRI (Visit 3) of the quadriceps to detect fatty infiltration that DXA may miss. All imageries will be performed either few days before or after the hip replacement for limited biais.
During the arthroplasty (Visit 2) a micro-biopsy of the gluteus medius is obtained through the surgical approach without additional incision, and bone-cartilage and synovium, normally discarded are collected and immediately transferred on ice to INSERM U1046 or U1183 for conditionning for cell culture, mechanistic assays and long-term storage (with participant opt-in for the biological collection). Within 15 days post-operatively (Visit 3) each participant undergoes a high-resolution quadriceps MRI and low-dose DXA to finalise muscle characterisation and obtain bone density. Telephone follow-ups at 3 months (Visit 4) and 6 months (Visit 5) repeat the Barthel Index and capture complications, readmissions and living arrangements; additional geriatric assessment is offered if recovery is unsatisfactory as part of routine care.
The primary endpoint is the variation in Barthel Index between baseline, 3 months, and 6 months. Key secondary analyses relate pre-operative sarcopenia metrics to: (i) in-vitro myoblast regeneration and endocrine function of skeletal muscle; (ii) circulating concentrations of muscle biomarkers (e.g. myostatin, follistatin, irisin, IL-6, IGF-1, lactate) ; and (iii) MRI-derived quadriceps composition. Laboratory procedures follow standardised culture and imaging protocols and include quality-controlled quantification of muscle satellite-cell (MuSC) proliferation, differentiation and senescence markers, as well as endocrine function including extracellular vesicle composition analysis, histological scoring of cartilage explants, and chondrocyte phenotypes and mesenchymal stem cells multipotency.
All data are entered into an electronic case-report form with automated range and consistency checks; monitoring is performed by the CHU Montpellier sponsor through on-site visits, central statistical surveillance and adherence to French Jardé Category-1 regulations (biopsy constitutes the main additional intervention). The statistical analysis plan, finalised before database lock, prespecifies descriptive statistics, non-parametric tests (Wilcoxon-Mann-Whitney, Fisher) for the primary endpoint, and exploratory Spearman correlations between sarcopenia measures, regenerative indices and functional change; given the pilot nature, 95 % confidence intervals will be reported without formal p-values.
Adverse events related to additional procedures are expected to be minimal (venepuncture, MRI without ionising radiation, DXA ≈0.001 mSv, and intra-operative muscle biopsy performed under the same anaesthesia). All events will be captured and reported according to Good Clinical Practice; a data-safety officer affiliated with the institutional vigilance unit will review safety quarterly. The study duration per participant is six months; the overall project, including analysis and dissemination, spans 18 months. Results, positive, negative or inconclusive, will be submitted to peer-reviewed journals and uploaded to ClinicalTrials.gov within one year of completion, in line with French and EU transparency requirements. By integrating in-vivo phenotyping, advanced imaging and ex-vivo regenerative testing across two complementary hip-surgery models, Hip-REGEN should generate mechanistic hypotheses and candidate biomarkers to guide future stratified rehabilitation or pre-habilitation trials in sarcopenic older adults.
Inclusion Criteria:
- Elderly subjects undergoing surgical hip replacement for fracture of the upper end of the femur or severe hip osteoarthritis.
Exclusion Criteria for both groups :
Exclusion criteria - Fracture group :
Exclusion criteria - Hip osteoarthritis group :
- Active inflammatory joint disease (rheumatoid arthritis, spondyloarthritis).
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Procedure: Total hip replacement · Biological: Blood sampling · Biological: Muscle biopsies · Biological: Collection of joint samples derived from surgical waste · Radiation: DXA · Other: MRI · Other: Handgrip strength test
Hip replacement is a surgical procedure performed as part of routine care for patients with a fracture of the upper end of the femur or severe osteoarthritis of the hip.
Four heparinized tubes of 5 ml of blood will be collected from each patient at inclusion. All blood samples will be stored in a biobank for subsequent analyses targeting biomarkers potentially associated with sarcopenia and muscle regeneration.
Performed during hip arthroplasty
Performed during hip arthroplasty
Within 15 days following the surgical procedure, during hospitalization/rehabilitation
Within 15 days following the surgical procedure, during hospitalization/rehabilitation
Measurement of handgrip strength using a hand dynamometer
Change from Baseline in the Barthel Index at 3 months post-operative
A 10-point shift is the minimal clinically important difference; after hip-fracture surgery a mean 25-point decline at 3 months is anticipated.
Time frame: Baseline and 3 months
Change from Baseline in the Barthel Index at 6 months post-operative
Time frame: Baseline and 6 months
Measurement of hand-grip strength via dynamometry
Assessment of preoperative sarcopenia severity
Time frame: Baseline
Measurement of appendicular lean mass by DXA
Assessment of preoperative sarcopenia severity
Time frame: Prior to surgery or within 7 days postoperatively
Measurement of quadriceps mass by MRI
Assessment of preoperative sarcopenia severity. Because DXA cannot differentiate intramuscular fat or connective tissue, 3-D Dixon/IDEAL MRI of the quadriceps-the muscle most affected by ageing-will segment contractile tissue and compute muscle mass (volume × 1.04 kg · L-¹).
Time frame: Prior to surgery or within 7 days postoperatively
Number of myoblastic progenitors at proliferation onset
Quantification, and correlation with Barthel-index at 3 month, of the number of myoblastic progenitor cells obtained after in-vitro proliferation for 3 days of primary human satellite cells isolated from \~25 mg gluteus micro-biopsies collected during surgery under general anaesthesia. The number of myoblasts will be determined by immunofluorescence staining and quantified using automated image analysis from at least five random microscopic fields per culture well (expressed as cells/mm² at day 3 of proliferation).
Time frame: Intraoperative
Mean myotube surface area at differentiation end
Quantification, and correlation with Barthel-index at 3 month, of the mean surface area of myotubes at the end of the differentiation phase from primary human satellite cells isolated from \~25 mg gluteus-medius micro-biopsies collected during surgery under general anaesthesia. Myotube surface area will be determined by immunofluorescence staining and quantified using automated image analysis from at least five random microscopic fields per culture well, expressed in square micrometres (µm²).
Time frame: Intraoperative
Proportion of senescent MSCs
Quantification, and correlation with Barthel-index at 3 month, of the proportion of senescent MSCs among primary MSC cultures isolated from bone fragments obtained during hip arthroplasty (surgical waste) by bone marrow flush. Senescence will be assessed using β-galactosidase staining, and the proportion of senescent cells will be calculated as the percentage of β-gal⁺ cells among total DAPI⁺ nuclei, averaged from at least five random microscopic fields per culture well (expressed as % of β-gal⁺ MSCs).
Time frame: Intraoperative
Number of chondrocytes obtained from MSCs at differentiation end
Quantification, and correlation with Barthel-index at 3 month, of the number of chondrocytes obtained at the end of the differentiation phase from primary human mesenchymal stromal cells (MSCs) cultured in chondrogenic differentiation medium. Differentiated cells will be identified by immunofluorescence staining or histological coloration and quantified using automated image analysis from at least five random microscopic fields per culture well, expressed as number of cells per mm².
Time frame: Intraoperative
Number of adipocytes obtained from MSCs at differentiation end
Quantification, and correlation with Barthel-index at 3 month, of the number of adipocytes obtained at the end of the differentiation phase from primary human mesenchymal stromal cells (MSCs) cultured in adipogenic differentiation medium. Differentiated cells will be identified by immunofluorescence staining or histological coloration and quantified using automated image analysis from at least five random microscopic fields per culture well, expressed as number of cells per mm².
Time frame: Intraoperative
Number of osteocytes obtained from MSCs at differentiation end.
Quantification, and correlation with Barthel-index at 3 month, of the number of osteocytes obtained at the end of the differentiation phase from primary human mesenchymal stromal cells (MSCs) cultured in osteogenic differentiation medium. Differentiated cells will be identified by immunofluorescence staining or histological coloration and quantified using automated image analysis from at least five random microscopic fields per culture well, expressed as number of cells per mm².
Time frame: Intraoperative
Serum concentation of myostatin
Preoperative circulating biomarkers predictive of post-arthrosplasty recovery will be identified and validated by quantifying candidate myokines in baseline serum via ELISA and multiplex assays and correlating with Barthel-index at 3 month.
Time frame: Baseline and 3 month
Serum concentation of myostatin
Preoperative circulating biomarkers predictive of post-arthrosplasty recovery will be identified and validated by quantifying candidate myokines in baseline serum via ELISA and multiplex assays and correlating with Barthel-index at 6 month.
Time frame: Baseline and 6 month
Serum concentation of follistatin
Preoperative circulating biomarkers predictive of post-arthrosplasty recovery will be identified and validated by quantifying candidate myokines in baseline serum via ELISA and multiplex assays and correlating with Barthel-index at 3 month.
Time frame: Baseline and 3 month
Serum concentation of follistatin
Preoperative circulating biomarkers predictive of post-arthrosplasty recovery will be identified and validated by quantifying candidate myokines in baseline serum via ELISA and multiplex assays and correlating with Barthel-index at 6 month.
Time frame: Baseline and 6 month
Serum concentation of irisin
Preoperative circulating biomarkers predictive of post-arthrosplasty recovery will be identified and validated by quantifying candidate myokines in baseline serum via ELISA and multiplex assays and correlating with Barthel-index at 3 month.
Time frame: Baseline and 3 month
Serum concentation of irisin
Preoperative circulating biomarkers predictive of post-arthrosplasty recovery will be identified and validated by quantifying candidate myokines in baseline serum via ELISA and multiplex assays and correlating with Barthel-index at 6 month.
Time frame: Baseline and 6 month
Serum concentation of IL-6
Preoperative circulating biomarkers predictive of post-arthrosplasty recovery will be identified and validated by quantifying candidate myokines in baseline serum via ELISA and multiplex assays and correlating with Barthel-index at 3 month.
Time frame: Baseline and 3 month
Serum concentation of IL-6
Preoperative circulating biomarkers predictive of post-arthrosplasty recovery will be identified and validated by quantifying candidate myokines in baseline serum via ELISA and multiplex assays and correlating with Barthel-index at 6 month.
Time frame: Baseline and 6 month
Serum concentation of IGF-1
Preoperative circulating biomarkers predictive of post-arthrosplasty recovery will be identified and validated by quantifying candidate myokines in baseline serum via ELISA and multiplex assays and correlating with Barthel-index at 3 month.
Time frame: Baseline and 3 month
Serum concentation of IGF-1
Preoperative circulating biomarkers predictive of post-arthrosplasty recovery will be identified and validated by quantifying candidate myokines in baseline serum via ELISA and multiplex assays and correlating with Barthel-index at 6 month.
Time frame: Baseline and 6 month
Plan to share: No
Started Aug 2026 (actual). Primary completion is estimated for Feb 2028, 18 months after the start.
Of 578 non-industry interventional studies with no phase under Osteoarthritis, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 51. This study's planned 18 months is below that.
Counting every sponsor, half of 713 studies reached it within 28 months; a quarter within 11 and three quarters within 57.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Montpellier →